Bayer/Regeneron's Eylea sees third eye indication in MYRROR
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals and Bayer's eye drug Eylea (aflibercept) has performed well in a Phase III trial in a new indication, myopic choroidal neovascularisation (mCNV), top-line data show. Bayer, which has marketing rights to the product outside the US, expects to make the first filing for the product in this indication by the end of the year in Asia, where this disease is particularly common.